Skip to main content

Table 3 Univariable analysis of potential preditive factors of overall survival

From: Accelerated hyperfractionation plus temozolomide in glioblastoma

 

Univariable analysis

Multivariable analysis

Variable

HR

95 % CI

p

Median OS [m]

HR

95 % CI

p

Age (< vs. > = median of 61 years)

1.18

0.8–1.7

0.4

14 vs. 12

Gender (m vs. f)

0.62

0.4–0.95

0.028 (*)

11 vs. 16

0.64

0.38–1.08

0.095

KPS (< vs. > = median of 70 %)

0.96

0.94–0.98

<0.001 (*)

9 vs. 15

MGMT-status (methylated vs. unmethylated)

1.68

1.08–2.61

0.021 (*)

16 vs. 11

1.89

1.158–3.09

0.011 (*)

Localization (other vs. central)

1.71

0.83–3.56

0.15

13 vs. 13

PTV (< vs. > = median of 337 ccm)

1.37

0.93–2.02

0.11

14 vs. 12

1.61

1–2.6

0.048 (*)

Subtotal resection or biopsy vs. gross total resection

0.64

0.43–0.95

0.025 (*)

11 vs. 15

0.62

0.39–0.98

0.041 (*)

Fractionation regimen (NFRT vs. AHFRT)

1.16

0.79–1.71

0.46

15 vs. 10

  1. (*) p-value ≤ 0.05, HR hazard ratio, CI confidence interval, OS overall survival, KPS Karnofsky performance status, MGMT O-6-methylguanine-DNA methyltransferase, PTV planning target volume, NFRT normofractionated radiotherapy, AHFRT accelerated hyperfractionated radiotherapy